Immunic, Inc. (IMUX)

$5.25

+0.33 (+6.71%)
Rating:
Recommendation:
-
Symbol IMUX
Price $5.25
Beta 1.999
Volume Avg. 0.74M
Market Cap 160.466M
Shares () -
52 Week Range 2.52-14.5
1y Target Est -
DCF Unlevered IMUX DCF ->
DCF Levered IMUX LDCF ->
ROE -61.80% Strong Sell
ROA -59.99% Strong Sell
Operating Margin -
Debt / Equity 8.45% Neutral
P/E -
P/B 1.24 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMUX news


Dr. Daniel Vitt
Healthcare
Biotechnology
NASDAQ Global Select

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.